🔎 Trials Near Me

Utama › Limfoma Sel-B › Michigan

Kajian klinikal Limfoma Sel-B di Michigan

7 kajian untuk Limfoma Sel-B sedang mencari peserta di lokasi di Michigan.

Bandar di Michigan

Teks kajian rasmi (Bahasa Inggeris)

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  • University of Michigan, Ann Arbor
  • The Cancer and Hematology Centers, Grand Rapids
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06742996

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

  • Clinical Trial Site, Detroit
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06393738

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Corewell Health, Grand Rapids
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

  • University of Michigan Rogel Cancer Center, Ann Arbor
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT07532525

DALY II USA/ MB-CART2019.1 for DLBCL

  • University of Michigan, Ann Arbor
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • C.S. Mott Children's Hospital, Ann Arbor
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.